Literature DB >> 32474708

Predictive factors of complete pathological response in patients with locally advanced rectal cancer.

Rebekah M Engel1,2,3, Karen Oliva4, Christine Koulis4, Raymond Yap4, Paul J McMurrick4.   

Abstract

PURPOSE: Patients with locally advanced rectal cancer who achieve pathologic complete response (pCR) following neoadjuvant therapy have better long-term outcomes and could be spared from the perioperative and long-term morbidity of rectal resection. The aim of this study was to identify factors that predict the ability to achieve pCR at completion of conventional neoadjuvant therapy, therefore determining their suitability for non-surgical management.
METHODS: A retrospective analysis was performed on data obtained from a prospectively maintained colorectal neoplasia database. Patients treated for biopsy-proven primary rectal adenocarcinoma between January 1, 2010, and February 28, 2018, who received neoadjuvant radiotherapy or chemoradiotherapy and had undergone surgical resection, were included in this study. Five-year oncologic outcome data was also obtained for 144 patients. Clinicopathological tumour characteristics and treatment regimens were analysed for correlation to clinical outcome.
RESULTS: Three hundred fifty-four patients met inclusion criteria for this study. We identified significant differences between patients achieving a pCR and those that did not for tumour type (adenocarcinoma vs. mucinous/signet ring; p = 0.008), pre-treatment serum CEA level (</≥ 2.5 μg/L; p = 0.003), neoadjuvant therapy type (short-course radiotherapy and long-course chemoradiotherapy; p = 0.008) and preoperative lymph node status (node-negative versus node-positive disease; p = 0.031). Additionally, this is the first report to our knowledge to identify a significant correlation with pCR and the degree of tumour fixity (mobile vs. fixed/tethered; p = 0.038).
CONCLUSIONS: This retrospective analysis identified factors that significantly impact a patients' ability to achieve a pCR, which may prove useful for prospectively selecting patients suitable for non-surgical management of disease.

Entities:  

Keywords:  Chemoradiotherapy; Neoadjuvant therapy; Pathological response; Rectal adenocarcinoma

Mesh:

Year:  2020        PMID: 32474708     DOI: 10.1007/s00384-020-03633-8

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  3 in total

1.  Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy.

Authors:  Su-Ping Guo; Chen Chen; Zhi-Fan Zeng; Qiao-Xuan Wang; Wu Jiang; Yuan-Hong Gao; Hui Chang
Journal:  Cancer Manag Res       Date:  2021-03-18       Impact factor: 3.989

2.  Pre-Treatment Computed Tomography Radiomics for Predicting the Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Retrospective Study.

Authors:  Yitao Mao; Qian Pei; Yan Fu; Haipeng Liu; Changyong Chen; Haiping Li; Guanghui Gong; Hongling Yin; Peipei Pang; Huashan Lin; Biaoxiang Xu; Hongyan Zai; Xiaoping Yi; Bihong T Chen
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

3.  Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data.

Authors:  Jia-Yi Li; Xuan-Zhang Huang; Peng Gao; Yong-Xi Song; Xiao-Wan Chen; Xing-Er Lv; Yv Fu; Qiong Xiao; Shi-Yv Ye; Zhen-Ning Wang
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.